Hospital Universitario Doce de Octubre, Madrid, Spain
Luis Paz-Ares graduated with a degree in Medicine from the Universidad Autonoma de Madrid in 1986, and completed a PhD in 1993 at the same University.
He was a postdoctoral European Society for Medical Oncology (ESMO) Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993–1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995.Dr Paz-Ares also completed a Master’s degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa, Madrid, Spain (2002–2003).
Between 2007-2014, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville, Spain. Dr Paz-Ares was then Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genitourinary tumours at the Hospital Universitario Doce de Octubre in Madrid, Spain (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).
Currently, Dr Paz-Ares is Chair of the Medical Oncology Department at the Hospital Universitario Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), in Madrid, Spain. Dr Paz-Ares’s research focuses on lung cancer and strategies for new therapy development, both in the lab and from a clinical point of view, and he has published more than 240 papers in peer- reviewed journals, including New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and many book chapters.
He is an active member of various scientific societies including American Society of Clinical Oncology (ASCO), ESMO, the International Association for the Study of Lung Cancer (IASLC) and collaborative groups, the European Organisation for Research and Treatment of Cancer (EORTC), the Spanish Lung Cancer Group and the International Germ Cell Cancer Collaborative Group.